Factors Influencing the Difference between Indonesian Case-Based Group Reimbursement and Medical Cost for Patients with Chronic Renal Disease Cases in Kasih Ibu Hospital, Surakarta
Abstract
Backgorund: JKN program has stipulated the INA CBGs reimbursement for the payment of treatment in referral health facilities, including for chronic renal disease which is a disease burden. This study aimed to analyze factors influencing the difference between Indonesian case-based group reimbursement and medical cost for patients with chronic renal disease cases in Kasih Ibu Hospital, Surakarta.
Subjects and Method: The study design was an analytic observational with cross sectional design. The study was conducted in Kasih Ibu Hospital Surakarta in August-October, 2017. With a total of 231 subjects sample which was selected by using proportional random sampling. The dependent variable was the difference between Indonesian case-based group reimbursement and medical cost. The independent variables were length of stay, type of class, medical treatment/ surgery, ICU treatment, and medication use. The data were analyzed using multiple linear regression.
Result: INA CBGs reimbursement (mean= Rp 6,120,000; SD= Rp 2,330,000) paid by BPJS Kesehatan was lower than actual hospital’s medical care cost (mean= Rp 7,070,000; SD= Rp 4,650,000). Factors profitable for hospitals were medical treatments/ surgery (b= 0.032; p= 0.552). Factors that inflicted financial loss were class 1 care (b= -0.104; p= 0.094), class 2 care (b= -0.033; p= 0.590) compared to class 3 care, length of stay (b= -0.541; p<0.001), medication use in accordance with national formulation (b= -0.183; p= 0.008) and the use of ICU (b= -0.045; p= 0.543). Patients who upgraded the class type (mean= Rp 5,526,074; SD= Rp 1,449,621) was higher than hospital’s medical cost for class 2 (mean= Rp 3,933,767; SD= Rp 1,887,900).
Conclusion: Mean of INA CBGs reimbursement on inpatient care of chronic renal disease is lower than the mean of hospital’s medical care cost. Length of stay and doctors’ compliance in using national medication formulation are important determinants to increase medical care cost. Hospital obtains profit from patients who upgrade type of class.
Key words: care cost, INA CBGs reimbursement, chronic renal disease
Correspondence: Mardhatillah. Kasih Ibu Hospital, Surakarta, Central Java. Email: mardhatillah.bws@gmail.com. Mobile: 089510610891.
Journal of Health Policy and Management (2017), 2(2): 117-127
https://doi.org/10.26911/thejhpm.2017.02.02.03
References
Aggarwal S, Topaloglu H, Kumar S (2014). Cost of inpatient hospitalization for ChronicKidney Disease in United States. Value in Health: Journal of International Society for Pharmaco economics and Outcomes Research, 1: A293.
Brown JB, Pedula KL, Balest AW (1999). The progressive cost of complication in type 2 diabetes mellitus. Arch Intern Med Journal. 159(16): 1873-80.
Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W (2014). Physician and pharmacist perceptions of generic medicines: What they think and how they differ. Health Policy Journal, 116: 214-223 .
Hidayat AM, Pribadi F, Marwati T (2016). Analisis Unit Cost Tindakan Appendektomi menggunakan Metode Activity Based Costing. Jurnal Asosiasi Dosen Muhammadiyah Magister Manajemen Rumah Sakit, UMY.
Howard JN, Harris I, Frank G, Kiptanui Z, Qiun J, Hansen R (2017). Influencers of Generic Drug Utilization: A Systematica Review. Research in Social and Administrative Pharmacy. Diakses di http://10.1016/j.sapharm.2017.08.001 tanggal 10 November 2017
Hudayani M, Andayani TM, Fudholi A. (2016). Komparasi Biaya Riil dengan Tarif INA CBGs dan Analisis Komponen Biaya yang Berpengaruh pada Pasien Stroke Hemoragi Rawat Inap Peserta JKN di Rumah Sakit Kabupaten Pekalongan. Thesis s2 Farmasi UGM. Yogyakarta.
Indonesia Renal Registry (2015). 8th Report of Indonesia Renal Registry 2015. PERNEFRI 2015.
Karabatsou D, Tsironi M, Tsigou E, Boutzouka E, Katsaulas T, Baltopaulus G. (2016). Variable Cost of ICU Care: A MicroCosting Analysis. Intensive Critical Care Nursing Journal, 35: 66-73.
Kalo Z, Harsanyi A, Vamossy I (2014). Investment Aspect of Generic Drug Policies in Countries with Severe Resource Constraints. Value in Health: Journal of International Society for Pharmacoeconomics and Outcomes Research, 17: A500.
National Kidney Foundation (2002). K/ DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39:S1-S266.
Peraturan Menteri Kesehatan Republik Indonesia Nomor 64 tahun 2016 tentang Perubahan atas Peraturan Menteri Kesehatan No. 52 Tahun 2014 tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan Program Jaminan Kesehatan.
Rinawati W (2015). Demotivasi atau Memotivasi. Kompasiana.com. Diakses di www.kompasiana.com/ pada 5 Juni 2017.
Riady M (2017). Tak Beralasan Jika RS Swasta Tolak BPJS Kesehatan. Diakses di www.republika.co.id pada tanggal 7 Juni 2017.
Rahayuningrum O, Tamtomo DG, Murti B (2016). Comparison between Hospital Inpatient Cost and INA-CBGs reimbursement of Inpatient Care in the National Health Insurance Scheme in Solo, Karanganyar, Boyolali District Central Java. Journal of Health Policy and Management 1(2): 102-112.
Sloan FA (2002). Valuing Health Care: Cost, Benefis and Effectiveness of Pharma ceuticals and Other Medical Technologies. United Kingdom: The Press Syndicate of Univercity of Cambridge.
Tamtomo DG (1995). Analisa Pembebanan Biaya untuk Menentukan Tarip Satuan Pelayanan pada Rumah Sakit Panti Waluyo, Surakarta. Laporan Penelitian Mandiri. Fakultas Kedokteran Universitas Sebelas Maret, Surakarta.
Thabrany H (2014). Jaminan Kesehatan Nasional. Jakarta: Raja Grafindo Persada.
Undang-undang No.11 Tahun 2014 tentang Badan Penyelenggara Jaminan Sosial.
